Specializing in Pharmaceuticals & Biotechnology info@mattsonjack.com
 
MATTSONJACK HOME CONSULTING SERVICES PRODUCTS CASE STUDIES ABOUT MATTSONJACK WORLDWIDE
 
MattsonJack Home > Case Studies > Prioritizing Commercial Investments

Case Studies

 Impact of Future Events
 Sales Force Productivity
 Pricing & Reimbursement
 Licensing & Acquisition (CDS)
 Prioritizing Commercial
Investments

 Prioritizing R&D Decisions
 New Product Launch
 Brand Optimization

 


Prioritizing Commercial Investments

STRATEGIC DECISION-MAKING ASSISTANCE FOR A GLOBAL FORTUNE 500 PHARMACEUTICAL FIRM
THE CHALLENGE   ADDRESSING THE CHALLENGE

The client was having difficulty objectively evaluating market opportunities that spanned seven therapeutic areas.

The client asked MattsonJack to construct a standardized and reproducible strategic decision-making approach that would prioritize market opportunities and link to the firm's strategic planning process.

MattsonJack's industry-specific capabilities enabled it to create a reproducible "market opportunity index" that compared each disease area's opportunities to another's.

CLIENT FEEDBACK
The client employed MattsonJack to update this deliverable annually — until the client acquired the internal resources to perform the analysis.
STRATEGY FOR AN EMERGING BIOPHARMA COMPANY: IDENTIFY AND EVALUATE COMMERCIALIZATION OPTIONS
     
THE CHALLENGE   ADDRESSING THE CHALLENGE

The client had a novel compound in Phase III development. As an emerging company with a limited commercial organization, it needed to determine the optimal commercialization strategy for this compound.

The client asked MattsonJack for assistance with the following:

  • outlining the time and resources required to create a viable and competitive commercial infrastructure that would enable the client to enter the U.S. market successfully
  • researching and analyzing commercialization options employed by other emerging biopharmaceutical firms
  • identifying, analyzing and evaluating the strengths and weaknesses of potential strategic commercialization alternatives, taking into account significant events that might occur before the anticipated product launch date

MattsonJack consultants used a multistep process that included:

  • analysis of the current and future competitive landscape and trends in the current market, including a detailed analysis of competitive products
  • evaluation of the product to determine how it most likely would compare to current and future competitors
  • identification, research, profiling and analysis of commercialization strategies employed by other emerging biopharmaceutical companies — insights obtained were employed to develop recommended commercial organization for the client
  • creation of a cost of commercialization model, including a proposed organizational structure for sales, marketing and support personnel
  • promotional response analysis to refine the required optimal resources
  • strategy scenario analysis, including scenario generation, analysis and rating of commercialization alternatives using a validated decision-analysis process
CLIENT FEEDBACK

The client's senior management was extremely pleased with both the process and the output — specifically complimenting the comprehensiveness of the analysis, commercial and market expertise and continuous involvement of senior consulting staff.

The CEO placed a high value on MattsonJack's willingness to "push back" and challenge the client's thinking.

The client has engaged MattsonJack on additional strategic projects.

   
     
 
PRIORITIZING COMMERCIAL INVESTMENT AND IMPROVING SALES FORCE PRODUCTIVITY
     
THE CHALLENGE   ADDRESSING THE CHALLENGE

The client, a regional pharmaceutical sales
and marketing company, had used MattsonJack's
services to help build its business through
in-licensing, co-promotion and product
acquisitions.

Several deals were completed. At the time
the client began considering an exit strategy,
it again asked for MattsonJack's assistance.

MattsonJack brought several suitors to the table, including two Japanese clients that were looking for U.S. entry strategies.

MattsonJack brokered the deal, which resulted in increased value enhancement for the owners.

CLIENT FEEDBACK

The client was purchased by a Big Pharma firm as the nucleus for its U.S. primary care business. The company sold for a significant, undisclosed amount.

   
 
 
©2005 The Mattson Jack Group, Inc. All rights reserved.
a WPP company
CONSULTING SERVICES  |  PRODUCTS  |  CASE STUDIES   |  CONTACT US   |  ABOUT MATTSONJACK
Tel: 314.469.7600 / 800.467.7606        Fax: 314.469.6794        info@mattsonjack.com
MattsonJack Analytics MattsonJack Corporate Development Davinci Oncology The Mattson Jack Group MattsonJack Site Map Contact MattsonJack